India rejects Novartis cancer drug patent

Marketplace Contributor Apr 1, 2013
HTML EMBED:
COPY

India rejects Novartis cancer drug patent

Marketplace Contributor Apr 1, 2013
HTML EMBED:
COPY

The Supreme Court in India has rejected an attempt by the Swiss drug maker Novartis to patent an update to a cancer treatment called Gleevec — spelled Glivec in some markets. The decision is expected to have a big impact on pharmaceutical companies and health organizations far outside the borders of India.

The BBC’s Rahul Tandon joins Marketplace Morning Report host Jeremy Hobson to discuss the global pharmaceutical market and the new patent ruling.

As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.

Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.

Donate today — in any amount — to become a Marketplace Investor. Now more than ever, your commitment makes a difference.